Literature suggests that GLP1-RAs combined with an antidiabetic drug in a different class, such as an SGLT2 inhibitor, may exhibit a synergistic improvement in glycemic control and provide multi-organ system benefits such as greater improvement of DKD than with GLP1-RA monotherapy [49]. Here, GLP1R is linked to diabetic kidney disease.